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Influenza is a contagious respiratory illness caused by influenza viruses. Influenza 
infection during pregnancy poses unique risks to pregnant women and infants, including 
severe symptoms and adverse pregnancy outcomes. However, many pregnant women do 
not receive the influenza vaccination. Reasons for low vaccine uptake are multifactorial, 
with the lack of a healthcare provider’s recommendation being a critical barrier. In this 
cluster-randomized controlled trial, we will examine the effect of a structured 
vaccine recommendation program for obstetric providers on the mean proportion of 
pregnant women who receive the influenza vaccination. Specifically, this trial will use 
a custom provider education program based on resources used in pediatric settings. A 
recommendation program that effectively increases influenza vaccine uptake could 
decrease morbidity and mortality among pregnant woman and infants. Additionally, this 
vaccine recommendation program could be extended across patient populations and 









CHAPTER 1: INTRODUCTION 
1.1 Background 
Influenza is an acute respiratory illness caused by influenza A or B viruses that 
occurs in outbreaks and epidemics worldwide, mainly during the winter season. The 
illness presents with signs and symptoms of upper and lower respiratory tract infection, 
along with systemic symptoms such as fever, headache, myalgia, and weakness.1 
Influenza is usually a self-limiting disease in the general population, but it is associated 
with increased morbidity and mortality in some high-risk populations including pregnant 
women.1 Influenza is responsible for a large disease burden worldwide; during the 2018-
2019 influenza season in the United States (US) alone, the virus caused 4.4 million 
infections, 58,000 hospitalizations, and 3,500 deaths.2 Influenza illness poses unique risks 
to pregnant women and infants. Throughout pregnancy, physiologic changes such as 
decreased functional residual lung capacity, mucus hypersecretion, increased cardiac 
output, and increased plasma blood volume alter the mother’s respiratory and 
cardiovascular systems. These physiologic changes, along with changes to the mother’s 
immune system, contribute to a modified response to infection and increased risk of 
complications during pregnancy.3 
Pregnant women have a greater risk of morbidity and mortality if infected with 
influenza during influenza pandemics and interpandemic periods.4 Throughout the 2009 
H1N1 pandemic, pregnant women accounted for 1% of the US population but 5% of 
H1N1-related deaths.5 In the influenza seasons spanning from 2010 through 2018, 
pregnant women accounted for up to 34% of influenza-associated hospitalizations among 
females aged 15-44 years.6 
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  In addition to maternal risks associated with influenza infection during pregnancy, 
infection also poses unique risks to the developing fetus, newborn infant, and infant less 
than six months old. Data from the 1918 H1N1 pandemic demonstrated an increased risk 
of pregnancy loss associated with influenza infection.7 Pregnant women who developed 
influenza had a significantly higher perinatal mortality rate (39 per 1,000 versus 7 per 
1,000 total US births), as well as increased frequency of preterm delivery (63.3% versus 
12.3% total US births), neonatal intensive care unit (ICU) admission (22% versus 6.1% 
total US births), and 5-minute Apgar scores less than six (29.2% versus 1.6% total US 
births) than non-pregnant women during the 2009 H1N1 influenza pandemic.8 Although 
influenza vaccinations are not approved for administration in infants less than six months, 
the vaccination of mothers during pregnancy may protect the infant in early life through 
the transfer of antibodies.9,10 The Centers for Disease Control and Prevention’s Advisory 
Committee on Immunization Practices (ACIP) affirms that influenza vaccination of the 
mother during pregnancy is the only accepted way to prevent influenza infection in 
infants, who are particularly vulnerable.11 
  Based on the risks that influenza infection poses, as well as the safety of the 
vaccine for pregnant women and their infants evidenced by current literature, the World 
Health Organization (WHO), the ACIP, and the American College of Obstetricians and 
Gynecologists (ACOG) recommend that all women who are or will be pregnant during 
influenza season receive a trivalent inactivated vaccine (TIV) as soon as it is available or 
at any time during pregnancy.11-14 Although 97.7% of US pregnant women in 2017 
visited a doctor or medical professional, influenza vaccine coverage among pregnant 
women was only 35.6%; as a result, nearly two-thirds of pregnant women were not 
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protected from influenza.15 Among women who received prenatal care, 58.7% reported 
being recommended and offered the vaccine, 15.6% received a recommendation but no 
offer for the vaccine, and 25.7% did not receive a recommendation or offer at all.15 
Vaccination uptake among these groups of women, respectively, was 52.4%, 26.1%, and 
5.7%.15 These estimates of influenza vaccine coverage remain far below the Office of 
Disease Prevention and Health Promotion’s Healthy People 2020 goal of 80% for 
pregnant women.16 Because of the large disease burden of influenza and the influenza-
associated complications and risks among pregnant women and infants, addressing low 
uptake of the vaccination in pregnant women should be a priority.  
  The reasons for the disparity between the Centers for Disease Control and 
Prevention (CDC)’s recommendations and vaccine uptake in pregnant women is 
multifaceted; however, the lowest percentages of influenza vaccination uptake in 
pregnant women are from women who are not offered, referred, or recommended the 
vaccine by their prenatal care provider.6 This highlights the effect that healthcare 
providers have on vaccine uptake and the sizeable consequences that absences of offers, 
referrals, and recommendations have on maternal and fetal health.  
1.2 Statement of the Problem 
  Influenza carries a large global disease burden and poses unique risks for pregnant 
women and infants.1,2 The WHO and the CDC recommend that all pregnant women 
receive the influenza vaccine during pregnancy; however, 64.4% of pregnant women in 
the US do not receive the vaccine, putting them and their infants at risk for developing 
severe influenza infection and adverse pregnancy outcomes.11,12,15 Many pregnant women 
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are not recommended, offered, or referred for the influenza vaccine by their prenatal care 
providers, which contributes considerably to low uptake.15  
Since the WHO and the CDC began recommending the influenza vaccine to all 
pregnant women during influenza season, researchers have investigated various 
interventions and their effectiveness in improving influenza vaccination uptake; however, 
current literature lacks sufficient randomized controlled trials, particularly those focused 
on intervening to improve dialogue between patients and healthcare providers. In 
neonatal and pediatric settings, the CDC offers providers structured recommendations, 
including communication tools to use with new parents.17 These recommendations have 
been successful in improving pediatric vaccine uptake in the US, with rates of children 
19-35 months receiving most vaccinations greater than 80-90%.17,18 Similar interventions 
have yet to be investigated thoroughly in the obstetric setting.  
1.3 Objectives and Goals 
The objective of this study is to examine the difference in the mean proportion of 
pregnant women who receive an influenza vaccine among those receiving prenatal care at 
obstetric clinics that provide a structured vaccine recommendation program versus usual 
care. The goal of this study is to increase influenza vaccine uptake among pregnant 
women, decrease influenza-associated adverse pregnancy outcomes, and decrease 
morbidity and mortality in both pregnant women and infants.  
1.4 Hypothesis  
Among pregnant women older than 18 years receiving prenatal care, there will be 
a statistically significant difference in the mean proportion of influenza vaccination 
uptake prior to date of delivery within the clusters of obstetric clinics receiving a 
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structured vaccine recommendation program compared to the clusters of obstetric clinics 
receiving usual care.  
1.5 Definitions 
Prenatal: Before birth; during or related to pregnancy. 
Cluster-Randomized Controlled Trial: Randomized-controlled trial in which groups of 
individuals, or clusters, are randomized instead of individuals. In this study, an obstetric 
clinic will be a cluster that is randomized into the intervention or control study arm.  
Obstetric: Related to childbirth and the associated processes. 
Structured Vaccine Recommendation Program: See section 3.4.1 Independent Variable 
(Intervention) and Appendix F, Appendix G, Appendix H, and Appendix I for details. 
Usual Care: Wide range of practices in which providers may individualize patient care. In 
this study, usual care will include any care that does not include the structured vaccine 
recommendation program. See section 3.4.3 Control Variable (Usual Care) for details. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
2.1 Introduction 
A systematic literature search was conducted from December 2020 through May 
2021 in PubMed, Ovid, and Cochrane databases. The search performed across the three 
databases was:  
(pregna* OR birth OR prenat* OR gestat*) AND (program* OR educat* OR 
intervention* OR recommend* OR dialogue* OR regimen* OR exposure*) AND 
(influenza* or flu) AND (vaccin* OR immuniz* OR inject*), with MeSH terms 
(pregnancy) and (influenza vaccines*). 
The search was limited to randomized controlled trials published during the years 
2010 through 2020 and to cross-sectional surveys, prospective cohort studies, 
retrospective cohort studies, and literature reviews published during the years 2015 
through 2020. All studies were retrieved into Endnote X9. We included studies that met 
the following criteria: 1) examined a population of pregnant women; 2) examined the 
influenza vaccination; and 3) evaluated vaccine uptake facilitators, vaccine uptake 
barriers, healthcare provider attitudes regarding patient vaccination, or involved 
interventions influencing vaccine uptake. We excluded studies that: 1) were written in a 
language other than English; 2) had a sample size less than 100 subjects; 3) exclusively 
focused on non-pregnant patients; 4) did not examine the influenza vaccine; and 5) 
exclusively discussed influenza vaccine safety. Each study was analyzed to identify its 
strengths and limitations to determine how our study can address current literature gaps. 
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2.2 Barriers to Influenza Vaccine Uptake 
Studies conducted in the United States and abroad have assessed barriers that 
decrease the likelihood pregnant women will receive the influenza vaccination.1-14  
Identifying these barriers is important when attempting to increase vaccine uptake; along 
with influencing uptake, these barriers may act as confounding variables in randomized 
controlled trials that examine a specific intervention’s effect on vaccine uptake. 
2.2.1 Lack of Healthcare Provider Recommendation 
Across the literature review, the most commonly reported barrier to influenza 
vaccine uptake was lack of healthcare provider recommendation.1-6 In a cross-sectional 
survey among pregnant women receiving prenatal care in Melbourne, Australia, the most 
commonly reported reason for non-vaccination was lack of provider recommendation 
(37%).1 This survey included women “intending” to receive vaccination, which may have 
overestimated vaccine uptake.1 In another survey from Australia, 61% of women 
randomly selected from a perinatal database were vaccinated during pregnancy (95% 
confidence interval [CI], 55-66%); of those unvaccinated, 53.6% reported they would 
have been vaccinated if a healthcare provider recommended it (95% CI, 45.9-61.3%).2 
86% of the self-reported vaccines in this study were verified by an immunization 
provider, decreasing potential overestimation from self-report bias.2 A cross-sectional 
survey conducted in Western Australia reported that the most common reason for being 
unimmunized in 2014 was lack of healthcare provider recommendation (48.5%, 95% CI 
42.8-54.1%).3 Random participant sampling increases this study’s generalizability. 
Researchers verified vaccine receipt with electronic medical record (EMR) data to limit 
self-report and recall bias.3  
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A cross-sectional survey of pregnant women attending five obstetric clinics in 
Italy reported that low vaccination adherence was associated with a lack of vaccination 
promotion by healthcare providers (odds ratio [OR] 0.16, 95% CI 0.04-0.69, p=0.01).5 
The high rate of refusal in this survey (96.1%) may have been biased by the high 
percentage of women in their second trimester of pregnancy (78%), who may have lower 
risk perception than women in their first trimester.5 In another cross-sectional survey 
conducted in Milan, Rome, and Jesi, Italy, the most prominent barrier, reported by 81% 
of women, was a healthcare provider’s lack of vaccine recommendation.7 This study only 
assessed women in the third trimester of pregnancy, who may have had lower presumed 
risk, thus decreasing vaccine uptake. Multivariate regression analyses could not be 
conducted due to low vaccination coverage (6.5%, 95% CI, 4.9-8.5%).7  
In a 2019 cross-sectional survey from two Singapore hospitals, the most reported 
reason for not receiving the influenza vaccine was lack of recommendation (45%).4 This 
study only surveyed patients attending public hospitals. Therefore, it may have 
underestimated the proportion of Singaporean women vaccinated.4 In a retrospective 
study conducted in Athens, Greece, 65.5% of mothers reported that they would have been 
vaccinated if their doctor recommended it (95% CI, 58.8-72.25). However, no 
recommendation was made in 73.6% of cases (95% CI, 67.4-79.8%).6  
2.2.2 Lack of Information about Influenza Infection and Influenza Vaccine 
 Another barrier to influenza vaccine uptake is a lack of information about 
influenza and its increased danger in pregnancy, as well as the safety and efficacy.4,8-11 In 
a cross-sectional survey of mothers who gave birth at one hospital in France from 2014-
2015, 46% did not know influenza can cause adverse outcomes in infants.8 Logistic 
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regression analyses accounted for confounding variables, including medical 
comorbidities, parity, education, and vaccine history.8  
In a cross-sectional survey of mothers who gave birth at one university hospital in 
Valencia, Spain, of the 48% of women who declined the influenza vaccination, 23% felt 
that they had insufficient information to make an informed decision.9 A retrospective 
cohort study also from Valencia reported that 16% of unvaccinated women “did not have 
adequate information”.11 This retrospective design allowed for data collection from an 
EMR, minimizing self-report bias.11  
A cross-sectional survey from Ireland randomly recruited pregnant women from 
prenatal clinics and found that only 57.6% knew that the influenza vaccine is safe in 
pregnancy, although 75% had heard about influenza vaccine in pregnancy.10 However, 
this study had a small patient sample size (n=113), which may limit its generalizability.10  
2.2.3 Concern for Safety of the Fetus 
 A 2018 literature review of 75 studies reported that vaccine safety perceptions 
were the most common barriers to accepting influenza vaccination.15 During the 2017-
2018 influenza season in the United States, an internet panel survey of 1,771 pregnant 
women found that 16% did not vaccinate their child because of concerns about safety 
risks to their infant.13 Although this survey had a large sample size, the nonprobability 
sample may not be generalizable across pregnant women in the United States.13 Another 
cross-sectional survey across clinics in Texas, New York, Illinois, and Pennsylvania 
found that the greatest barrier to influenza vaccination uptake was concern for the health 
and safety of the baby (44.5%).14 However, 59% of the sample was white and 71.5% was 
highly educated, which may affect this study’s generalizability.14 In a prospective cohort 
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study from an obstetric clinic in Greece, the most common reason for refusing the 
vaccine was “fear of adverse events for their fetus” (27%).12  
The fourteen studies discussed above illustrate ubiquitous barriers to influenza 
vaccination from eight countries between 2012 and 2019, with respective reported uptake 
in pregnancy ranging widely from 3.9-77.9%.1-14 These barriers underscore both the need 
for prenatal care providers to recommend that pregnant women get vaccinated and the 
need to inform patients about the vaccine’s safety and the health risks posed to them and 
their unvaccinated infant.16 
2.3 Facilitators for Influenza Vaccine Uptake 
 Studies have also assessed facilitators that increase the likelihood pregnant 
women will receive the influenza vaccination.1-3,7,10,13,14,17-24 Since facilitators may also 
act as confounding variables, it is important to understand their independent effects on 
vaccination uptake. 
2.3.1 Healthcare Provider Recommendation 
 Healthcare provider recommendation is the most commonly reported facilitator of 
influenza vaccine uptake in pregnant women.1,2,7,13,14,17-20,25,26 One systematic review and 
meta-analysis of 49 studies reported that pregnant women were ten to twelve times more 
likely to receive the vaccine if a healthcare provider recommended it.25 Another review of 
32 studies from 15 countries similarly found that healthcare provider recommendation 
was the most common determinant of vaccination uptake.26 A cross-sectional survey 
conducted across the 2017-2018 influenza season in the United States found that of the 
66.6% of women who received a provider recommendation, 63.8% of those were 
vaccinated.13 Of the 19% who did not receive a recommendation, only 30.1% were 
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vaccinated.13 Another cross-sectional survey across four American clinics found that 
accepting the influenza vaccine was associated with a healthcare provider’s 
recommendation (OR 2.60, p<0.01).14  
Another cross-sectional survey reported that from September 2017-March 2018, 
provider recommendation was the most common reason for receiving the influenza 
vaccine among pregnant women in Ireland (39%).20 In Italy, vaccine recommendation 
from a healthcare provider during pregnancy was a significant predictor of vaccine 
uptake (OR 28, 95% CI 14-63, p<0.001).7 During Australia’s 2016 influenza season, 
healthcare provider recommendation was the strongest predictor of influenza vaccination 
uptake (OR 30, 95% CI 16-56, p<0.001).1 In a 2013 cross-sectional survey conducted at 
two hospitals in Managua, Nicaragua, vaccine recommendation from a healthcare 
provider was positively associated with receipt (adjusted odds ratio [AOR] 14.22, 95% CI 
10.45-19.33, p<0.01)17. A cross-sectional survey conducted among women at prenatal 
clinics in Zhejiang, China from January-March 2014 found 93% of pregnant women 
agreed that “if a physician or nurse recommended the influenza vaccine, I would get 
vaccinated” (p<0.001), despite only 76% were willing to receive the vaccine otherwise.18 
This study likely overestimated the population’s vaccination status because it merely 
reports willingness to accept the vaccine.18 In a cross-sectional survey of pregnant 
women and obstetric physicians in Rajavithi, Thailand, physician recommendation was 
the only facilitator associated with vaccination uptake. Women were 2.3-times more 
likely to get vaccinated when a physician recommended the vaccine (AOR 2.3, 95% CI 
1.4-3.8, p<0.01).19 This study may have underestimated vaccination proportion, since it 
only accounted for uptake within 30 days of recruitment.19 
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2.3.2 History of Previous Influenza Vaccination 
 Influenza vaccination in previous influenza seasons is also associated with 
vaccine uptake during pregnancy.1,7,14,18,21-23 A retrospective EMR review of pregnancies 
that overlapped with influenza seasons between 2002 and 2011 in integrated healthcare 
systems throughout California, Colorado, Oregon, Washington, and Wisconsin, found 
that vaccination in a previous influenza season was a significant predictor of vaccination 
during pregnancy (OR 4.66, 95% CI 4.57-4.75).21 However, it is unclear whether this 
study is generalizable to pregnant women in the United States because it did not record 
ethnicity data. Moreover, the study may underestimate vaccine proportions because it did 
not account for vaccines obtained outside of health systems utilizing this EMR.21 A cross-
sectional survey across clinics in Texas, New York, Illinois, and Pennsylvania reported 
that previously accepting an influenza vaccine increased uptake probability during 
pregnancy (4.87, p<0.01).14  
Previous influenza vaccination was also associated with increased vaccination 
uptake among women who received prenatal care at a large university hospital in France 
between November 2014 and June 2015 (OR 4.1, 95% CI 3.1-5.5, p<0.001).23 Among 
pregnant women in Melbourne, Australia, previous receipt of the influenza vaccine was a 
predictor of vaccine uptake (OR 8, 95% CI 5-15, p<0.001).1 The same was true for 
hospitals in Italy (OR 28, 95% CI 14-63, p<0.001).7 A retrospective cohort study found 
that willingness to receive influenza vaccination during pregnancy was associated with 
ever having a previous influenza vaccination among pregnant women attending eight 
hospitals or affiliated prenatal care clinics in Beijing, China between March and April, 
2016 (AOR 6.74, 95% CI 1.71-26.4, p=0.006).22 The high household income (63.4% 
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>5,000 renminbi [RMB], unit of Chinese currency) and education status (75.3% with a 
bachelor’s degree or higher) of the study’s sample population suggest the findings are not 
generalizable to all of China.22 
2.3.3 Desire for Neonatal Protection 
 83% of 2,045 women who received prenatal care at a large university hospital in 
France between November 2014 and June 2015 stated that their primary motivator for 
vaccination was “protection of her baby”.23 Similarly, pregnant women in Western 
Australia reported that the most common reason for accepting the influenza vaccine was 
“to protect her baby” (92.8%, 95% CI 89.9-95.7%, p=0.002).3 Mothers across Italian 
hospitals in 2018 who knew that the influenza vaccine protects newborns during their 
first months of life were more likely to be vaccinated (OR 6.2, 95% CI 3.14-14, 
p<0.001).7  
2.3.4 High Perceived Infection Susceptibility, Vaccine Safety, and Vaccine Benefit 
Women are more likely to receive the influenza vaccine during pregnancy if they 
are aware of: 1) their increased susceptibility to infection; 2) increased risk of severe 
disease; and 3) the vaccination’s benefits.10,18,22 A cross-sectional survey of women 
attending prenatal clinics in Zhejiang, China from January-March 2014 reported the 
following factors were associated with vaccination uptake: high perceived susceptibility 
of influenza infection (AOR 1.75, 95% CI 1.36-2.08); high perceived levels of influenza 
severity (AOR 1.62, 95% CI 1.25-1.95); and high perceived levels of vaccination benefit 
(1.97, 95% CI 1.76-2.21).18 Moreover, an Irish cross-sectional survey found a 
relationship between knowing the influenza vaccine is safe and receiving it (p<0.001).10 
Similarly, a retrospective cohort study from Beijing, China reported that high perceived 
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benefit of vaccination was associated with vaccination uptake (AOR 1.67, 95% CI 1.00-
2.79, p=0.05).22  
2.3.5 Other Factors Associated with Influenza Vaccine Uptake in Pregnancy 
Older maternal age has been associated with influenza vaccine uptake in 
pregnancy.21,24 Older age was a predictor of vaccination during pregnancy that 
overlapped with 2002-2011 influenza seasons in the US (OR 1.71, 95% CI 1.16, 1.17).21 
A 2015 English retrospective cohort study reported age was a significant predictor of 
whether 4,817 mothers who gave birth at South London Hospital that year received the 
influenza vaccination; specifically, women above 26 years of age were more likely to 
receive the vaccine than women below 26 years of age (OR 1.84, 95% CI 1.27-2.67, 
p<0.001).24 This study’s retrospective design limits self-report bias with EMR review.24  
Nulliparity, or never having given birth, has also been associated with increased 
influenza vaccine uptake in pregnancy.23,24 Nulliparity was associated with increased 
vaccine uptake among women who received prenatal care at a large hospital in France 
(41.0% vs. 31.3%, OR 2.5, 95% CI 1.7-3.7, p=0.001).23 A 2018 English retrospective 
cohort study found a similar association (p<0.001).24 First-time pregnant women may 
attend more appointments, which may increase the likelihood they will receive a vaccine 
recommendation. Women with more prenatal visits during influenza season were also 
more likely to receive influenza vaccination.17,21,24 In Managua, Nicaragua in 2013, 
having four or more prenatal visits was associated with vaccine receipt (AOR 2.58, 95% 
CI 1.15-5.81, p<0.01).17 Similarly, an English 2018 retrospective cohort study reported 
that increased number of prenatal visits during fall and winter seasons was associated 
with increased vaccination uptake (p<0.001).24 Furthermore, an American retrospective 
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cohort study found that longer overlap between pregnancy and influenza season was 
associated with increased vaccination uptake (AOR 4.28, 95% CI 4.15-4.41).21 
Pregnant women with comorbidities may be more likely to receive the influenza 
vaccination during pregnancy.21,23 In the United States, a retrospective cohort study 
conducted during influenza seasons from 2002 to 2012 reported the following high-risk 
medical conditions are associated with increased vaccination uptake during pregnancy: 
chronic cardiac, pulmonary, liver, or renal disease, immunosuppression, diabetes 
mellitus, malignancy, or a neurologic or musculoskeletal condition (AOR 1.26, 95% CI 
1.24-1.28).21 Medical comorbidities were associated with increased vaccination uptake 
among pregnant women in France from 2014 to 2015 (p=0.02).23  
Health literacy and education level have been shown to have both positive and 
negative effects on influenza vaccination uptake in pregnant women.9,22,27 The National 
Center for Health Statistics conducted a cross-sectional survey of 5 million pregnant 
women between the 2012-2016 influenza seasons in the United States and found the 
likelihood of vaccination uptake increased if the mother had a bachelor’s degree or higher 
as compared to mothers with a high school diploma or less (OR 2.09, 95% CI 1.35-3.22, 
p=0.002).27 This study’s strengths are its large sample size and comprehensive data 
encompassing five influenza seasons. However, its cross-sectional design merely shows 
associations, not causation.27 A 2016 retrospective cohort study from Beijing, China 
reported having more knowledge about influenza was associated with vaccination uptake 
(AOR 82.2, 95% CI 21.7-311.1, p<0.001).22 This suggests pregnant women with a lower 
education level are less likely to receive the influenza vaccination.22,27  
  However, in a cross-sectional survey of mothers at a university hospital in Spain 
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between November 2015 and May 2016, mothers who did not receive the influenza 
vaccination during pregnancy had higher health literacy than those who received the 
vaccination (p=0.022).9 Notably, this statistically significant difference was only seen 
when health literacy was measured by the Spanish Assessment of Health Literacy 
(SAHLSA_50), and was not seen with two different screening tools (p=0.372, p=0.942).9 
One explanation for this discrepancy is the study’s small sample size; another explanation 
is these screening tools’ reliability may have been compromised because they have not 
been used extensively in Spanish-speaking populations.9 Further research should 
investigate whether increased health literacy is truly associated with vaccination refusal.  
 A provider’s ability to offer an in-clinic influenza vaccine shortly after 
recommendation is also associated with increased uptake.28 A cross-sectional survey 
conducted at three prenatal clinics in Paris reported that women who attended a clinic 
with vaccines available for in-clinic administration had higher vaccine uptake than those 
who attended a clinic requiring administration at a pharmacy (35.4% vs. 2.7%, p<0.01).28 
Patients were reimbursed for in-clinic and pharmacy-administered vaccinations to control 
for cost as a confounding variable. This may make the results ungeneralizable because 
pharmacy-administered vaccines in France may require payments.28 
The above studies illustrate ubiquitous facilitators for influenza vaccination from 
ten countries. These facilitators should be considered when investigating methods to 
increase vaccination uptake and controlled for as potential confounding variables in 
randomized controlled trials. 
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2.4 Healthcare Provider Attitudes and Practices 
 Other cross-sectional studies surveyed healthcare providers to investigate their 
attitudes and practices about recommending the influenza vaccine to prenatal 
patients.15,22,29-32 An exploratory literature review of 75 studies found the most commonly 
cited barriers among American healthcare providers to recommending maternal influenza 
immunization were financial concerns including inadequate reimbursement, payment, or 
complexity of billing.15  
  Some physicians believe insufficient evidence exists regarding the influenza 
vaccine’s efficacy in pregnancy, which decreases recommendation and administration 
rates.29 One cross-sectional survey of obstetrician-gynecologists (OB-GYNs) in the 
country of Georgia from June-July 2015 found only 43% of physicians recommended the 
vaccine to prenatal patients, despite that 88% perceived influenza to be a serious 
infectious disease.29 Of those who do not regularly recommend the vaccine, 75% 
perceived insufficient evidence supports administering the vaccination in pregnancy. This 
study surveyed OB-GYNs in both public and private clinics, so it considered the opinions 
of physicians working in multiple settings. However, 82% of the physicians in this 
sample were female, which may decrease its generalizability to male physicians.29  
Some physicians report lack of knowledge about or insufficient training in giving 
pregnant women the influenza vaccine.22,30 A retrospective cohort study reported only 
19.4% of obstetricians in eight Beijing, China hospitals were willing to recommend the 
vaccine to pregnant patients. Moreover, 15.2% were aware China’s National Health 
Commission recommends the vaccine during pregnancy.22,30 A web-based cross-sectional 
survey of 3,441 midwives and nurses in England reported that 56% had not received 
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training on vaccinations in pregnancy and that healthcare providers who received 
immunization training were more confident in giving advice to pregnant women than 
those who did not (84%, 95% CI 81-85%).30 This survey was sent to all registered 
midwives and nurses in England and had a 10% response rate, which may limit the data’s 
generalizability to the larger population.30 
 Some physicians report concern about vaccine safety and efficacy in pregnant 
patients.31,32 A cross-sectional survey of 150 attending or resident obstetric and family 
physicians at six hospitals in Israel reported 37% perceived the vaccine is dangerous or 
controversial in pregnancy, even though 92.5% were aware the health ministry 
recommends vaccination to pregnant women.31 This study surveyed physicians from 
major medical centers and small hospitals, which helped make the sample representative 
of the Israeli physician population.31 In Catalonia, Spain, a cross-sectional survey of 194 
OB-GYNs and midwives reported 53.6% knew the influenza vaccine was indicated, yet 
only 43.4% prescribed it to prenatal patients. The main reason for this discrepancy was 
concerns of adverse side effects (25.9%).32 However, 91.8% of the sample were female, 
70% were midwives, and 79% were younger than 55 years, thus the results are less 
generalizable to male providers, physicians, and older providers.32  
Although healthcare providers report financial concerns, perceptions of 
insufficient vaccine evidence, lack of knowledge or training, and concerns about vaccine 
safety and efficacy, they also report openness to receiving more education about the 
topic.29,32 Of OB-GYNs surveyed in Georgia, 93% would be receptive to receiving 
additional education on vaccination.29 Of OB-GYNs and midwives in Spain, 92.3% 
reported a willingness to receive vaccination training.32 
 20 
2.5 Limitations of Cross-Sectional Surveys 
Many of the studies reviewed above are cross-sectional surveys, which merely 
capture data from single moments in time; thus, they can only establish association, not 
causation.1-5,7-10,13,14,17-20,23,27-34 Furthermore, self-report or recall bias are inherent risks in 
studies that rely on self-reported data. Self-report bias may lead to overestimated 
vaccination coverage, and recall bias may lead to either overestimated or underestimated 
vaccination coverage.1-8,10,13,14,17,18,20,23,27,28,30-34 For example, 77.9% of women in one 
study reported accepting the vaccine, but only 36.1% had confirmed vaccinations in their 
EMR.14 Although some women may have received the vaccination at a facility without an 
EMR, it is likely that self-report or recall bias plays a role in this discrepancy. Moreover, 
small sample sizes may limit the generalizability of findings reported in some cross-
sectional surveys. 6,9-11,20,28,29,31,32 Some studies were conducted at a single hospital or 
obstetric clinic, which may also limit their generalizability.1,6,8,9,11-13,19,23,24 
2.6 Interventions for Influenza Vaccine Uptake in Pregnant Women 
 Few studies have evaluated the effects of various interventions on the proportion 
of pregnant women vaccinated. Studies that discuss these interventions have evaluated 
pamphlet, text message, internet, patient, and provider-centered interventions. 
2.6.1 Pamphlet-Centered Interventions 
 In a 2014 randomized controlled trial, Meharry et al. investigated using a patient-
centered pamphlet and benefit statements to increase vaccine uptake in pregnancy.35 The 
study randomized women from three Connecticut obstetric clinics into three groups. One 
intervention group received an educational pamphlet about influenza, risks to the mother 
and fetus, and the vaccine’s safety profile. Another intervention group received both the 
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pamphlet and a benefit statement, “If you have the flu shot during pregnancy, you will 
also help protect your baby against influenza from birth to six months”.35 Clinic nurses 
were asked to report the primary outcome measure, which was whether the patient 
received the vaccination within two months of enrollment.35 Chi-square tests found no 
significant differences in basic characteristics between groups. Women in both the 
pamphlet group and pamphlet plus benefit statement group had higher vaccine uptake 
than the control group that received usual care (79.2%, p=0.009 vs. 86.1%, p<0.001 vs. 
46.9%, respectively).35 These findings suggest easy-to-access patient education and a 
simple statement about infant protection can increase vaccination uptake.35 The pamphlet 
used in this study was constructed from literature evidence and piloted before use. The 
sample was limited to Connecticut, which has higher average influenza vaccine uptake in 
pregnancy than the national average (66.9% vs. 36.5%, respectively).35 This limits the 
study’s generalizability. Additionally, the primary outcome measure of vaccination 
within two months of enrollment may not account for participants who received the 
vaccination later in their pregnancy course.35  
 A prospective cohort study conducted at an outpatient clinic in Greece found 
providing pregnant women with an informational pamphlet about influenza vaccine 
safety and infection risks was associated with a ten-fold increase in vaccination 
proportion (20% vs. 2%, p<0.02).12 Prospective cohort study findings are limited because 
they can only declare an association between the intervention and vaccine uptake.12 
2.6.2 Text-Centered Interventions 
 From October to November 2012, Text4baby, a free, national text service built in 
collaboration with the CDC and ACOG, provided vaccine information and reminders to 
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pregnant women after enrollment.33 In a cross-sectional survey, Jordan et al. evaluated 
whether Text4baby’s vaccination reminders improved vaccine uptake among pregnant 
women.33 The study recruited women through an international survey sampling website. 
The primary outcome was self-reported influenza vaccination between October and 
January. Researchers found Text4baby reminder recipients were more likely than non-
participants to report receiving the vaccination during pregnancy after adjusting for 
length of Text4baby enrollment, gestational age, language, and poverty group (AOR 2.0, 
95% CI 1.4-2.9, p=0.01).33 The use of a survey sampling website provided the study with 
a large, geographically diverse sample, and external validity was supported by the similar 
vaccination rates among Text4baby participants compared to the CDC’s national rate for 
pregnant women reported at this time (51% vs. 47%, respectively).33  
In 2013-2014, Buschar et al. also used internet panel surveys to compare self-
reported influenza vaccination rates during pregnancy among Text4baby participants and 
non-participants in the United States.34 The study’s primary outcome was self-reported 
influenza vaccination before delivery. Adjusted prevalence ratios (APRs) and 
multivariable logistic regressions were calculated to control for ethnicity, education 
status, poverty status, comorbidities, and provider recommendation and/or offer to 
vaccinate. Text4baby participants were more likely to report vaccination, regardless of 
receipt of provider recommendation and offer to vaccinate (provider recommendation or 
offer APR=1.29, 95% CI 1.21-1.37; no provider recommendation or offer APR=3.39, 
95% CI 2.03-5.67).34 However, women who enrolled in Text4baby may have been more 
health-conscious and more likely to get vaccinated, which may have biased the results.34 
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Also, comparison groups had unbalanced subject numbers, with only 377 women in the 
Text4baby group and 2,824 in the non-participant group.34 
At an obstetric clinic in Toronto from November 2013 through March 2014, 
Yudin et al. sent pregnant women two, weekly text messages for four weeks that 
reinforced the influenza vaccine recommendation and emphasized its safety during 
pregnancy and breastfeeding. The objective was to increase the proportion of pregnant 
women who would receive the vaccination.36 After enrollment and consent in the clinic 
waiting area, women were randomized into intervention (text) or control (no text) groups. 
The primary outcome was vaccination uptake, assessed by post-partum telephone call. 
Researchers used Fisher’s exact tests to compare vaccination rates and logistic regression 
to adjust for characteristics independently associated with vaccine uptake, including 
marital status (married) (p<0.001), higher household income (p=0.03), and history of 
influenza vaccination (p<0.001). With 80% power and alpha set at 5%, weekly text 
messages did not increase the likelihood of receiving the influenza vaccine among 
pregnant women (31% vs. 27%, p=0.51).36 32% of women in the intervention group 
reported feeling that there were too many messages, thus irritation may have contributed 
to vaccine refusal. The study sample came from an urban care center where 88% of the 
sample had post-secondary education or higher, so these results may not be generalizable 
to women in different settings.36 
 A randomized-controlled trial by Moniz et al. also used text messaging to 
improve influenza vaccination rates in pregnancy.37 Pregnant women at an obstetric clinic 
in Pittsburgh, Pennsylvania were randomized into two groups. Both groups received 
usual prenatal care and completed pre- and post-intervention surveys. The comparison 
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group received twelve, weekly text messages with information about general preventive 
health, whereas the intervention group received these text messages with information 
about both preventative health and influenza vaccine safety and benefit in pregnancy. The 
primary outcome was influenza vaccine uptake, measured by prenatal record review. 
Using 80% power and intention-to-treat protocol, there was no significant difference 
between vaccination uptake in either group, meaning this text message education had a 
limited effect on uptake (33% vs. 31%, 95% CI -11.1-14.5%, p=0.88).37 In post-
intervention surveys, 52% of women reported they would have received the vaccine if 
recommended by their prenatal care provider, thus a provider’s recommendation may be 
a more effective method for increasing uptake.37 The study used EMRs to obtain outcome 
data, which limited self-report bias. Many participants had less than a high school 
education (90%) and predominantly public or no insurance (88%), which may limit the 
data’s generalizability.37  
2.6.3 Internet-Centered Interventions 
One randomized controlled trial assessed the use of a website containing vaccine 
information and interactive social media modules, such as an interactive blog, discussion 
forum, and chatroom on influenza vaccination uptake in pregnant women.38 At one 
obstetric clinic in Colorado, women in the third trimester of pregnancy with internet 
access were recruited and randomized into three groups. The first group received access 
to a website with information on maternal vaccination, national recommendations, and 
common vaccine questions. The second group received access to both the website and the 
interactive social media modules. The control group received usual care. The primary 
outcome was vaccination before delivery, extracted from EMRs. Women in both 
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intervention arms had a higher proportion of vaccine uptake than the usual care arm, 
while no difference existed between intervention arms (57% intervention vs. 35% 
control, p=0.01).38 Although it appeared that women who utilized these internet 
interventions were more likely to receive the vaccine, website access analysis revealed 
only 35% of women in the intervention arm visited the website. This suggests other 
unstudied reasons accounted for this increased vaccine uptake.38 Additionally, only third-
trimester patients were included, which may have contributed to the sample’s vaccine 
hesitancy, as women in the third trimester may have lower presumed risk.7,38  
Another randomized controlled trial assessed the effectiveness of a pre-visit 
educational video on vaccination rates in pregnant women at three obstetric clinics in 
Cleveland, Ohio.39 Women randomized into the intervention group watched a 3.5-minute 
video titled, “Protect Yourself, Protect Your Baby” before seeing their prenatal care 
provider, who was blinded from the patient’s random allocation. The primary outcome 
was influenza receipt on the day of intervention, obtained by EMR review. The video did 
not impact vaccination rates (28% intervention, 25% control, p=0.7). However, the 
intervention did influence belief that vaccination can protect the mother and baby as a 
secondary outcome (p=0.003, p=0.001, respectively).39 This short video was unable to 
substantially influence vaccination uptake. This primary outcome, vaccination receipt on 
the day of intervention, may have missed patients who were influenced by the video, but 
received the influenza vaccination later in their pregnancy course. These results are also 
limited by the study’s small sample size (n=105).39  
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2.6.4 Patient-Centered Interventions 
 One randomized controlled trial at prenatal clinics in Hong Kong evaluated the 
effect of 10 minutes of pre-appointment patient education about vaccine safety, efficacy, 
and recommendations on influenza vaccine uptake before delivery.40 Vaccination rates 
were higher in the brief education group than in the usual care group (21.1% vs. 10%, 
p=0.006), which suggests a brief education session is a successful method for increasing 
uptake.40 Strengths of this study include the use of random allocation and concealment to 
minimize bias in treatment assignment, the ease and consistency of providing a 10-
minute intervention by a single nurse, and minimal attrition bias due to on-site 
intervention. This study was limited by potential self-report bias and effect 
overestimation resulting from the use of self-report data, and research nurses and 
participants not being blinded due to the nature of the intervention.40  
Another randomized controlled trial among 276 pregnant women of color in 
Atlanta, Georgia compared the effect on vaccine uptake of “gain-frame messages” that 
emphasize positive outcomes of vaccination versus “loss-frame messages” that 
emphasize negative outcomes of not vaccinating.41 Researchers found that neither gain 
nor loss messages were associated with increased likelihood of immunization during 
pregnancy (p=0.166, p=0.154, respectively).41 However, healthcare provider 
recommendation was correlated with increased vaccine uptake as a secondary outcome 
(p=0.013). Only 46% of the participants completed the post-partum questionnaire, thus 
the study had considerable loss-to-follow up.41 
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2.6.5 Provider-Centered Interventions 
 In 2016, an integrative literature review of 22 articles affirmed that although 
provider recommendation was the most important predictor of vaccine acceptance among 
pregnant women, there has been minimal provider-centered research.42 Only two cluster-
randomized controlled trials have examined the effectiveness of provider-centered 
interventions on increasing influenza vaccination uptake in pregnant women.43 In 2015, 
Chamberlain et al. assessed the effectiveness of a multimodal vaccination promotion 
package on improving prenatal uptake.43 Eleven obstetric practices in Georgia were pair-
matched on the following factors associated with vaccination uptake: in-clinic vaccine 
administration capability, percentage of patients with Medicaid, and estimated proportion 
of prenatal patients vaccinated in the previous influenza season. Patients were then 
randomized into two arms using stratified randomization. Practices in the intervention 
arm received practice-level (a vaccine champion, posters, brochures), provider-level 
(talking-points for promoting vaccination), and patient-level intervention components 
(informational videos, maps to local pharmacies that provide vaccines), while practices in 
the control arm provided usual care. Researchers used the intention-to-treat principle to 
calculate risk differences and ratios and covariate-adjusted models were used for 
statistical analyses.43 No significant difference in vaccine rates existed between 
intervention and control groups after the intervention (RD 3.6%, 95% CI -4.0-11.2%, 
p=0.30).43  
Another cluster-randomized controlled trial in Colorado in 2019 also used a 
multimodal intervention to encourage influenza vaccination in pregnant women.44 Eight 
obstetric clinics were randomized using covariate constrains to balance study arms by 
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clinic size and percentage of patients with Medicaid, both of which may have influenced 
the primary outcome, vaccine receipt before delivery. Clinics in the intervention arm had 
staff and provider trainings about best practice guidelines for vaccines, influenza vaccine 
purchasing assistance, standing order implementation, and patient education materials. 
Control clinics received usual care.44 Like Chamberlain et al., O’Leary et al. did not find 
a statistically significant difference in influenza vaccine uptake between the intervention 
and control arms (27% baseline both arms, 29% intervention vs. 41% control, p=0.15).44 
The pair-matched cluster design of these studies helped control for factors known to 
influence vaccination uptake, and verification with EMR data mitigated self-report 
bias.43,44 The multimodal design of these interventions, however, makes it difficult to 
tease out which components were unsuccessful. Interventions with too many components 
may have been difficult for providers to implement, which likely contributed to the lack 
of effect seen in these provider-centered studies.43,44 
 Three retrospective studies used provider-centered interventions to increase the 
rate of influenza vaccination among pregnant women.45-47 One study during the 2008-
2009 influenza season at an obstetric clinic in Wisconsin examined the effect of an EMR 
“best-practice alert,” which alerted healthcare providers when a prenatal patient had not 
yet received the vaccination.45 The primary outcome of vaccination during pregnancy 
was collected through EMR review and the proportion of pregnant women vaccinated 
was compared to the clinic’s pre-intervention proportion during the 2007-2008 influenza 
season. The 2008-2009 vaccination rate was higher, which suggests a best-practice alert 
for providers may be helpful for increasing vaccination uptake (61% vs. 42%, p<0.01).45  
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A 2012 retrospective cohort study compared vaccination rates among pregnant 
women seen at an obstetric clinic in October-November 2003 with those seen in October-
November 2005 after provider-focused reminders to recommend influenza vaccination 
were placed on each patient’s chart.46 This study reported an increase in influenza 
vaccination rates after implementing a provider-focused chart reminder, with no 
significant differences in covariates including maternal age, ethnicity, language, 
insurance status, education status, or chronic illness diagnoses (15% vs. 52%, p<0.001).46  
Another retrospective cohort study conducted at a tertiary hospital in Australia 
examined the effectiveness of a multi-component educational program for prenatal care 
providers on influenza vaccine uptake in pregnant women.47 The program, conducted in 
2011, included provider education and reminders, information brochures for patients, and 
increased vaccine access. The proportion of women vaccinated in 2011 was compared to 
that in 2010, before the program was implemented. Researchers found that influenza 
vaccination coverage increased after the intervention (30% vs. 40%, p = 0.03).47 These 
three studies were conducted at single clinics, limiting their generalizability.45-47 
Additionally, these retrospective cohort studies cannot claim that the interventions caused 
this vaccination proportion increase because they merely report on associations.45-47   
 One prospective study conducted at Bridgeport Hospital assessed the impact of a 
provider-centered intervention on influenza vaccination uptake in pregnant women.48 
This intervention was implemented over the 2008-2009 influenza season and consisted of 
a multi-component educational program with provider-focused components, including e-
mail reminders to providers about recommendation guidelines, information posters 
advertising influenza vaccines, and vaccine offers during prenatal ultrasounds. Compared 
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with patients who received usual prenatal care during the 2007-2008 influenza season, 
influenza vaccination rates increased from 19% to 31% after the intervention 
(p<0.0001).48 Like the interventions implemented in prior cluster-randomized controlled 
trials, it is difficult to analyze which subsets of the multi-component intervention were 
the most effective in increasing vaccine uptake.48  
Another prospective cohort study conducted at a maternity hospital in Australia 
compared the proportion of pregnant women vaccinated against influenza before and 
after the implementation of a midwife vaccination program.49 Researchers reported a 
higher vaccination rate after the implementation of the midwife program compared to 
those who delivered before the program was implemented (AOR 5.95, 95% CI 2.13-
16.61, p<0.001).49 Maternal age, country of birth, and parity were independently 
associated with vaccination rates and were adjusted for using multivariable logistic 
regression. It is difficult to assess whether the results of this study are reproducible 
because it reported minimal details about the vaccination program.49  
2.7 Conclusion 
 Low influenza vaccination uptake in pregnant women is a worldwide problem. 
The fundamental importance of a healthcare provider’s recommendation of indicated 
maternal influenza vaccination cannot be overstated. Across cross-sectional studies, the 
most commonly reported barrier to vaccination uptake was the lack of a healthcare 
provider’s recommendation, and the most commonly reported facilitator for uptake was a 
healthcare provider’s recommendation.1-7,13,14,17-20 Consequently, providers are in a 
unique position to increase influenza vaccination rates in pregnant women. Yet, many 
providers feel like they have insufficient training and knowledge about the vaccine in 
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pregnancy to make recommendations.22,29-32 Since provider recommendations are the 
most effective facilitator for vaccination uptake, a study with an objective of increasing 
influenza vaccination uptake in pregnant women should aim to increase provider 
recommendation rates. Providers should receive training, education about current 
guidelines, and literature about influenza vaccination in pregnant women so that they feel 
comfortable making these recommendations.  
A cluster-randomized controlled trial would best allow for the implementation of 
a provider-centered intervention at the clinic level, where all providers in a clinic receive 
an educational intervention. The cluster-randomized design also allows clinics to be pair-
matched based on factors associated with vaccination uptake, which from the studies 
reviewed above, include clinic size, vaccine availability for in-house administration, 
percentage of patients with Medicaid insurance, and EMR use. It is also important to 
control for variables that may independently influence the primary outcome, influenza 
vaccination prior to date of delivery. From the studies reviewed above, patient-level 
variables to consider include maternal age, gestational age, parity, race, ethnicity, number 
of prenatal visits during influenza season, medical comorbidities, history of previous 
influenza vaccination, education level, and employment status. 
 Current literature lacks randomized controlled trials that aim to increase influenza 
vaccination uptake in pregnant women through provider-centered interventions. A 2016 
systematic review of eleven studies affirmed that high-quality, randomized controlled 
trials are needed to develop successful maternal influenza vaccination programs.50 To 
date, only two cluster-randomized controlled trials with more than 100 participants have 
taken this approach, and neither study reported statistically significant findings.43,44,51 The 
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multimodal design of these studies makes it difficult to discern which intervention 
components were unsuccessful. Therefore, a cluster-randomized controlled trial should 
construct a simple intervention that is easy for providers to implement.43,44  
 Interventions used to increase vaccination rates in neonatal and pediatric settings 
show promise for increasing influenza vaccination rates in pregnant women. For 
example, training providers to use presumptive communication with new parents has 
been successful in improving vaccination uptake.52-56 The CDC provides pediatric 
providers with structured dialogues to reference when speaking to new parents about 
vaccinating children. These dialogues include presumptive recommendations, which 
assume parents will vaccinate their children, stating initially, “your child needs DTaP, 
Hib, and Hepatitis B shots today.”51,55 If parents express concern, providers give strong 
recommendations and personal anecdotes, such as: “I strongly recommend your child get 
these vaccines today” or “this office has given thousands of doses of vaccines and we 
have never seen a serious reaction.”55 If parents still decline vaccination after this 
dialogue, further promotion strategies include re-addressing the topic at the next visit and 
sharing fact sheets provided by the CDC.51 These simple, structured interventions have 
successfully maintained high pediatric vaccination rates. Greater than 80% to 90% of 
children ages 19-35 months in the United States receive most vaccinations.52,55,56 Similar 
interventions have yet to be tested thoroughly in the obstetric setting. Interventions like 
this could have a powerful impact on vaccination uptake, given healthcare providers’ 
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CHAPTER 3: STUDY METHODS 
3.1 Study Design 
This study will be a cluster-randomized controlled trial involving the 
randomization of obstetric clinics in the Greater New Haven area into intervention or 
control arms. The unit of randomization and analysis will be the obstetric clinic, which 
will minimize contamination. All obstetric healthcare providers at clinics randomized 
into the intervention arm will be trained uniformly on the structured vaccine 
recommendation program, which will be utilized consistently among all prenatal patients 
at these clinics. Because patients may be seen by multiple different healthcare providers 
at an obstetric clinic throughout their pregnancy, all healthcare providers at clinics 
randomized into the intervention arm will use the structured vaccine recommendation 
program with all prenatal patients.  
3.2 Study Population, Sampling, and Recruitment 
3.2.1 Recruitment of Obstetric Clinics 
All obstetric clinics within a 30-mile radius of Yale New Haven Hospital will be 
identified, approached, and evaluated based on the inclusion and exclusion criteria 
(Table 1). For a clinic to be eligible for inclusion, all obstetric healthcare providers 
working in the clinic must provide informed, written consent to participate in the study 
(Appendix A). Participation will first include randomization into either study arm; if 
randomized into the intervention arm, participation will then include attending a 1-hour 
training about the intervention and committing to consistently using the structured 
vaccine recommendation program with prenatal patients throughout the 7-month 
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intervention period. After providing consent, obstetric providers will be asked to 
complete a questionnaire with basic information about their clinic (Appendix B).  
Table 1: Obstetric Clinic Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
 
• Clinic location within 30-mile radius of Yale 
New Haven Hospital 
• Current population  50 prenatal patients 
• All obstetric providers in the clinic (including 
physicians, nurse midwives, physician 
associates, nurse practitioners, and nurses) have 
provided informed, written consent and have 
agreed to consistently utilize the structured 
vaccine recommendation program with their 
prenatal patients throughout the 7-month 
intervention period 
• If a clinic does not use an EMR, a clinic staff 
member has agreed to collect and report post-
partum data for consented patient subjects 
 
 
• Clinic location not within 30-mile radius of 
Yale New Haven Hospital 
• Current population < 50 prenatal patients 
• All obstetric providers in the clinic have not 
provided consent to participate and/or have not 
agreed to consistently utilize the structured 
vaccine recommendation program with their 
prenatal patients throughout the 7-month study 
period 
• If a clinic does not use an EMR, a clinic staff 
member has not agreed to collect and report 
post-partum data for consented patient subjects 
 
3.2.2 Recruitment of Patient Subjects 
Within eligible clinics in both intervention and control arms, all women who 
present for prenatal care, either at the start of the study period or at their initial prenatal 
visit, will be handed a brief eligibility and interest questionnaire (Appendix C). 
Interested women who meet inclusion and exclusion criteria will be telephoned by a 
researcher (Table 2). The researcher will provide the patient with more information and 
explain the consent form, which will be sent either electronically to the patient’s email or 
in-person at their next prenatal visit, if preferred (Appendix D). Clinics will also be given 
the option of having a recruiting researcher remain in their clinic waiting area; if this 
option is preferred, all women who present for prenatal care during the study period will 
be approached in the clinic waiting area by a researcher. Patients will be recruited using 
the same screening checklist to determine eligibility (Appendix C, Table 2). Regardless 
 39 
of the selected recruitment method, informed, written consent will be obtained from all 
patient subjects (Appendix D). Following consent, patient subjects will be asked to 
complete a brief demographic questionnaire (Appendix E). 
Table 2: Patient Subject Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
 
• Age  18 years 
• Pregnant (confirmed by prenatal ultrasound) 
• Ability to read or understand English 
• No known contraindication to influenza vaccine 
• Has not received the 2022-2023 influenza 
vaccine 
 
• Age < 18 years 
• Not currently pregnant 
• Inability to read or understand English 
• Known contraindication to influenza vaccine 
(life-threatening allergy to a vaccine component 
including egg protein, history of an anaphylactic 
reaction to a vaccine)1 




3.3 Subject Protection and Confidentiality 
 We will submit an application to the Yale Institutional Review Board (IRB), 
which must be approved prior to study initiation. We will include two Consent for 
Participation in a Research Project 200 FR. 1 forms, which include an invitation to 
participate, description of the research study, potential risks and benefits, economic 
considerations, confidentiality and privacy agreements, and information about voluntary 
participation and withdrawal (Appendix A, Appendix D). Because pregnant women are 
a vulnerable research population, it is important that they are aware of the minor risks and 
common side effects associated with influenza vaccination. All participants, including 
healthcare providers and patient subjects, must provide written, informed consent.  
 All research team members must complete Human Subjects Protection Training 
and Health Insurance Portability and Accountability (HIPAA) privacy training and 
provide evidence of certification to the Yale IRB. All health information of patient 
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subjects will remain protected under HIPAA compliance. Patient information will be de-
identified and coded, and all data will be kept on an encrypted web-based data 
management system that is only accessible by approved researchers. Once analyses are 
complete, we will destroy all participant data. 
3.4 Study Variables, Measures, and Operationalization 
3.4.1 Assignment of Intervention 
Cluster randomization will be used to allocate obstetric clinics into intervention or 
control arms. Each outpatient clinic will be considered a cluster. Participating clinics will 
be pair-matched on clinic-level covariates associated with vaccine uptake, which include 
clinic size, percentage of clinic patients with Medicaid insurance, percentage of clinic 
patients with self-pay or no insurance, vaccine availability for in-clinic administration, 
and the clinic’s use of an EMR. Within each pair-matched group, one obstetric clinic will 
then be randomly assigned to receive the intervention (structured vaccine 
recommendation program), and one will serve as a control (usual care). Random 
assignment of condition (intervention vs. control) will be determined by coin-toss by a 
researcher otherwise unaffiliated with the study. 
3.4.2 Independent Variable (Intervention) 
The structured vaccine recommendation program will begin with a 1-hour training 
with obstetric healthcare providers during their clinic’s lunch hour. To limit variability in 
intervention training, the same researcher will discuss the Talking with Pregnant Women 
about Vaccines resource guide with each clinic assigned to the intervention arm 
(Appendix F). The resource guide will present a structured, three-step method for 
healthcare providers to use when discussing vaccines with their patients, which includes 
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assuming women will vaccinate, giving a strong recommendation, and listening and 
responding to patients’ questions. It also provides guidance on what to do if women 
refuse the vaccine, as well as additional vaccine-related resources for both providers and 
patients. This resource guide was created using the CDC’s Talking with Parents about 
Vaccines for Infants fact sheet, tailored to address obstetric providers.2 After explaining 
how to use the resource guide, the researcher will answer any questions that obstetric 
providers have. Providers will be given PDF and paper copies of the resource guide for 
future reference.  
In addition to the 1-hour training, healthcare providers will also receive PDF and 
paper copies of two reader-friendly fact sheets created by the CDC, to be distributed to 
patients who request more information about the vaccine and its safety during pregnancy. 
These fact sheets are titled Pregnant? You Need a Flu Shot! and Pregnancy and 
Vaccination (Appendix G, Appendix H).  
Finally, each healthcare provider at clinics assigned to the intervention arm will 
receive biweekly email reminders that aim to encourage adherence to the structured 
vaccine recommendation program (Appendix I). Healthcare providers can reply to the 
biweekly email with specific questions or concerns, as well as request paper or PDF 
copies of the resource guide and fact sheets. 
3.4.3 Dependent Variable (Outcome) 
The primary study outcome will be the receival of the influenza vaccination prior 
to date of delivery. There will be no secondary outcomes. 
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3.4.4 Control Variable (Usual Care) 
The obstetric clinics who are not randomly allocated to receive the intervention 
will be assigned to the control group, or “usual care”. Usual care encompasses a wide 
range of practices in which providers may individualize patient care. In this study, usual 
care will include any care that does not include the structured vaccine recommendation 
program beginning with a 1-hour healthcare provider training. Clinics assigned to the 
usual care arm will not be provided with resource guides, fact sheets, or biweekly emails.  
3.4.5 Covariates 
Table 3: Patient-Level and Clinic-Level Covariates 
Patient-Level Covariates Clinic-Level Covariates 
• Maternal age 
• Ethnicity/race 
• Gestational age at time of recruitment 
• Parity 
• Education level 
• Employment status 
• Health insurance status 
• Influenza vaccination history 
• Number of prenatal visits during influenza 
season (October 2022 through April 2023) 
• Gestational age on date of vaccination 
• Medical comorbidities 
• Clinic size (total deliveries in 2021) 
• Percentage of clinic patients with Medicaid 
insurance in 2021 
• Percentage of clinic patients with self-pay or 
no insurance in 2021 
• Influenza vaccine availability for in-clinic 
administration 
• Clinic EMR use 
 
 
3.5 Blinding of Intervention and Outcome 
Patient subjects presenting for prenatal care at participating clinics will need to 
provide informed written consent to participate in the study but will not be specifically 
told whether they are receiving the intervention or control. Due to the nature of the 
intervention, healthcare providers will not be blinded to their random allocation, as they 
will be required to undergo training and carry out the structured vaccine recommendation 
program with their patients. The researchers involved in training healthcare providers and 
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responding to biweekly healthcare provider emails will not be blinded to the clinic’s 
random allocation. However, research staff involved in consenting patient subjects, 
collecting baseline demographic information, collecting outcome data, and performing 
statistical analyses will be blinded to clinic random allocations. 
3.6 Data Collection 
Clinic-level data including clinic size, percentage of patients with Medicaid 
insurance, percentage of patients with self-pay or no insurance, vaccine availability for 
in-clinic administration, and EMR use will be collected during clinic recruitment and 
used to pair-match clinics before conducting stratified randomization (Appendix B). 
Patient-level data collection will begin during the intervention period. Data 
involving patient information will be de-identified, coded, and stored in an encrypted 
web-based data management system that is only accessible by approved researchers 
(Appendix J). Data collected during the intervention period will include information 
from the baseline demographic questionnaire, which will be completed in the clinic 
waiting area immediately after written consent (Appendix E).  
Patient-level data collection will also continue after the 7-month intervention 
period. Post-partum data, which will include influenza vaccination receipt prior to date of 
delivery, gestational age on date of vaccination, number of prenatal visits during the 
intervention period, and medical comorbidities will be collected primarily through EMR 
review. For patients who attended obstetric clinics that did not use an EMR, post-partum 
data will be collected from a clinic staff member, to whom the role of storing this data for 
patient subjects will have been assigned and accepted during the clinic recruitment 
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process. All post-partum data will be collected by a researcher who is blinded to the 
random allocation of the patient and clinic.  
3.7 Sample Size Calculation 
Sample size will be calculated based upon detecting a 35% absolute increase in 
the mean proportion of pregnant women receiving an influenza vaccine among 
intervention clinics compared to control clinics. A standardized effect size of 35% is 
based upon previous studies following multi-component interventions to improve vaccine 
coverage in pregnant women.3,4 The randomization of clinics rather than participant 
subjects to avoid contamination between study groups leads to a decrease in statistical 
efficacy. Individuals may have chosen the cluster to which they belong, for example, by 
choosing to live in a particular area, or choosing a healthcare provider with similar 
demographic characteristics to them; therefore, an intracluster correlation coefficient 
(ICC) will be used because patient subjects within a cluster cannot be assumed to be 
independent from each other. Using a 35% standardized effect size, 2-tailed significance 
level of 0.05(∝), and ICC of 0.01 from a cluster-randomized controlled trial evaluating 
similar outcomes, we will require 10 obstetric clinics (5 intervention, 5 control) with 50 
pregnant women per clinic to obtain statistical power of 0.801 (Appendix K).5 We 
expect negligible loss to follow-up at the participant level because most of the data 
collection will come from EMR review or clinic records. 
3.8 Statistical Analysis 
Statistical analysis for the primary outcome will be conducted at the cluster and 
individual levels. At the cluster level, mean proportions will be calculated as a summary 
measure for each cluster. A student’s t-test will be used to compare cluster mean 
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proportions; if a regression analysis is needed to adjust for differences in cluster 
characteristics, such a test, most likely a mixed-effects linear regression model, will need 
to include adjustment for the ICC.6 
At the individual level, we will use chi-square tests to compare influenza 
vaccination before delivery, reported as a dichotomous outcome, and receival of the 
structured vaccine recommendation program. We will also examine the relationships 
between the primary outcome and patient-level covariates in Table 3. Dichotomous 
outcomes and categorical variables will be compared using chi-square tests. Continuous 
variables will be reported as a mean and standard deviation and compared using student’s 
t-tests. Multiple logistic regression will be used for patient-level covariates found to have 
an independent influence on the primary outcome.  
Each estimate will be accompanied by a 95% confidence interval (CI). A 5% level 
of significance (p≤0.05) will be considered statistically significant. An intention-to-treat 
approach will be used to compare outcomes between the study arms, with participants 
analyzed according to the study arm which their obstetric clinic was randomly assigned. 
Statistical analyses will be conducted by researchers blinded to participant allocations. 
3.9 Timeline and Resources 
Obstetric clinic recruitment will occur from June through August 2022. Pair-
matching and stratified randomization of obstetric clinics, as well as researcher training, 
will occur from in August 2022. Healthcare provider training at clinics assigned to the 
intervention arm will occur in September 2022. Recruitment of patient subjects and 
intervention, as well as baseline demographic data collection will occur during the 2022-
2023 influenza season from October 2022 through April 2023. Post-partum data 
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collection will continue for 10 months, from May 2023 through February 2024, to ensure 
that all pregnant women have delivered. Data analysis will occur following post-partum 
data collection. See Figure 1 for the proposed study timeline.  
Figure 1: Study Timeline  
Year 2022 2023 2024 
Month June July August September October – April May - February  
Obstetric Clinic 
Recruitment 
                     
Researcher 
Training 
                     
Healthcare 
Provider Training 
                     
Study Period 
(Intervention) 
                     
Demographic Data 
Collection 
                     
Post-Partum Data 
Collection 
                     
 
 This study will require multiple researchers. Two to three researchers will assist 
in obstetric clinic recruitment, one of whom will be trained to conduct healthcare 
provider training sessions. This study will also require researchers to recruit patient 
subjects in clinic waiting areas throughout the intervention period; the number of 
participating clinics will determine the number of recruitment researchers needed. One 
researcher will send and respond to biweekly adherence emails. Throughout the 
intervention, post-partum data collection, and statistical analysis periods, one to two 
blinded researchers will assist with data collection, data entry, and statistical analyses. In 
obstetric clinics that do not use an EMR, one clinic staff member must agree to collect 
post-partum data on consented participant subjects. 
 This study will require multiple computers for communication, data collection, 
and statistical analyses. Patient subject recruitment and intervention will occur in 
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previously established obstetric clinic waiting areas and exam rooms. Printing materials 
will be needed to supply healthcare providers with resource guides and fact sheets. 
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CHAPTER 4: CONCLUSION 
4.1 Advantages and Disadvantages 
 This study has multiple advantages. The cluster-randomized design limits 
contamination, which can dilute observed differences between study arms and affect 
reliability and validity of the results. The design maintains the internal validity of an 
individually randomized trial while enhancing its external validity through various 
methodological features. It includes representative patient subjects from a variety of 
urban and suburban settings, diverse outpatient clinics, healthcare providers with 
different credentials and patient care approaches, and a comparison condition that 
represents usual care rather than no treatment.1 Pair-matching clinics prior to 
randomization decreases the effects of potential confounding variables, while also 
including clinics with different baseline characteristics to increase the generalizability of 
study results. The intention-to-treat approach used in statistical analyses helps protect 
randomization from bias due to imbalanced baseline characteristics. The intervention 
itself is cost-effective and requires minimal resources. Healthcare providers only need to 
attend a 1-hour training and will be provided with all resources required to implement the 
intervention, which should make study participation inviting.  
This study also has multiple limitations. The intervention will be applied to clinics 
in a single state and affiliated with one health system, therefore the results may not be 
generalizable to other locations or health systems. Based on the intervention nature, 
neither healthcare providers nor researchers involved in healthcare provider training will 
be blinded to the random allocations of clinics. This cluster-randomized controlled trial 
has an inherent risk of selection bias, as particular patient groups with similar qualities 
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may be more or less likely to participate. To decrease this risk, all patients at participating 
clinics will be screened for eligibility and welcomed to participate. The structured 
vaccine recommendation program requires healthcare provider adherence, which is 
difficult to monitor. Low adherence could make it difficult to detect differences between 
conditions. Biweekly adherence emails will be sent to promote the adherence of 
providers to the vaccine recommendation program. Some healthcare providers in the 
usual care group may promote influenza vaccination more than others, which may also 
contribute to difficulty detecting differences between conditions. Compared with 
individually randomized trials, cluster-randomized trials are more complex to design, 
require more participants to obtain equivalent statistical power, and require complex 
analysis.2 The use of an intracluster correlation coefficient (ICC) has a major effect on 
sample size calculation and data analysis, most notably requiring more patient subjects 
than an individually randomized trial to retain statistical power.2 
4.2 Clinical and Public Health Significance 
Influenza infection is associated with increased risk of morbidity and mortality in 
pregnant women and infants.3 During influenza pandemics and interpandemic periods, 
influenza infection during pregnancy was associated with greater risk of death, 
hospitalization, and pregnancy loss.4-6 Influenza infection also presents risks to the 
developing fetus, newborn infant, and infant less than six month old, with an increased 
risk of preterm delivery, neonatal intensive care unit (ICU) admission, and low newborn 
Apgar scores.7 This structured vaccine recommendation program, if successful in 
increasing vaccine uptake, could decrease influenza-associated adverse pregnancy 
outcomes and decrease morbidity and mortality in both pregnant women and infants. 
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Efforts to inform pregnant women about the influenza vaccine and encourage vaccination 
are vital for achieving the Healthy People target of 80% vaccination coverage.8  
 A structured vaccine recommendation program that effectively increases 
influenza vaccine uptake in pregnant women could be applied to patient populations 
beyond pregnant women and to other high-burden infectious diseases. Since the United 
States Food and Drug Administration (FDA) authorized the first COVID-19 vaccines, 
public health experts and healthcare providers have been working to decrease vaccine 
hesitancy. Patients consider their healthcare providers to be their most trusted source of 
information when it comes to vaccines, so healthcare providers play a critical role in 
helping people choose COVID-19 vaccination.9 The three-step resource guide modified 
for obstetric providers in this study emphasizes assuming patients will vaccinate, giving a 
strong recommendation, and listening and responding to patients’ questions; this method 
could be easily adopted by providers in any medical field to decrease vaccine hesitancy, 
increase uptake, and decrease transmission and illness for any infectious disease, 
including COVID-19.  
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Appendix A: Consent Form (Healthcare Providers) 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR.1 (2016-2) 
 
YALE UNIVERSITY SCHOOL OF MEDICINE 
Study Title: Guidelines For Influenza Vaccination Uptake In Pregnant Women: A 
Cluster-Randomized Controlled Trial 
Principle Investigators: Katherine H. Campbell, MD, MPH 
Invitation to Participate and Description of Project 
You are invited to participate in a research study designed to examine the effect of a 
structured vaccine recommendation program for obstetric providers on the mean 
proportion of pregnant women who receive the influenza vaccination. You have been 
asked to participate because you are a healthcare provider at an obstetric clinic near Yale 
New Haven Hospital.  
 
To decide whether you wish to be a part of this research study, you should know enough 
about its risks and benefits to make an informed decision. This consent form gives you 
detailed information about the research study, which a member of the research team will 
discuss with you. This discussion should go over all aspects of this research: its purpose, 
the procedures that will be performed, any risks of the procedures, and possible benefits. 
Once you understand the study, you will be asked if you wish to participate; if so, you 
will be asked to sign this form. 
 
Description of Procedures 
Because patients may be seen by multiple different obstetric providers at your clinic 
throughout their pregnancy, all physicians, midwives, physician assistants, nurse 
practitioners, and/or nurses in your clinic must agree to participate and provide informed, 
written consent to be included in our study. If your obstetric clinic agrees to participate, 
our research team will provide each healthcare provider with a brief questionnaire about 
your clinic. These questions will help us pair-match your clinic with another like yours.  
 
Once your clinic has been pair-matched, it will be randomized into either the intervention 
or control study arm. If randomized into the intervention arm, participation will begin 
with a 1-hour educational training about our structured influenza vaccine 
recommendation program and our easy-to-use resource guide. This 1-hour training will 
be conducted by a member of our research team at your clinic during your lunch hour, for 
your convenience. You will have the opportunity to ask our researcher questions about 
the intervention during this time.  
 
After this training, you will be expected to utilize the structured vaccine recommendation 
program with your prenatal patients consistently throughout the 7-month study period, 
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which takes place during the 2022-2023 influenza season from October 2022 through 
April 2023. You will be provided both paper and PDF copies of our resource guide, as 
well as paper and PDF copies of fact sheets created by the CDC for distribution to your 
patients. Finally, you will receive a biweekly email from our research team with 
opportunities to ask specific questions or request more materials.  
 
Following the initial questionnaire about your clinic, no data about you will be collected. 
If your clinic agrees to participate, your clinic will have the option of distributing an 
eligibility/interest questionnaire to patients at their initial prenatal visit, or if you would 
prefer, a member of our research team will greet patients in your waiting area using a 
screening checklist to determine their eligibility. Written, informed consent will be 
obtained from eligible women. Following consent, subjects will be asked to complete a 
brief demographic questionnaire. After each patient’s delivery, blinded research staff will 
collect limited, specific information about her health and medical care from the electronic 
medical record (EMR). If your clinic does not use an EMR for patient health records, we 
will need a clinic staff member to collect this information and present it to us at the end 
of the post-partum data collection period (May 2023 through February 2024). Post-
partum data for each patient subject will include influenza vaccine receipt prior to date of 
delivery, gestational age on date of vaccination, number of prenatal visits during the 
intervention period (October 2022 through April 2023), and medical comorbidities. 
 
Risks and Inconveniences 
We identify no physical risks to you associated with the study. Few inconveniences 
include attending a 1-hour training session with a researcher about the intervention. This 
session will occur at your obstetric clinic for your convenience. Agreement to participate 
also includes agreement to utilize the structured vaccine recommendation program 
consistently with each of your prenatal patients throughout the 7-month intervention 
period from October 2022 through April 2023. A member of our research team will send 
you a biweekly email to encourage adherence. If you so choose, a member of our 
research team will remain in your clinic’s waiting area to greet patients and determine 
their eligibility throughout the study period, which may be a minor inconvenience for 
your clinic.  
 
Benefits 
Potential benefits of this study include the opportunity to increase influenza vaccination 
uptake among pregnant women, decrease influenza-associated adverse pregnancy 
outcomes, and decrease morbidity and mortality in both pregnant women and infants. 
 
Economic Considerations 
There are no costs associated with participation in this study. However, if your clinic 
provides in-clinic administration of the influenza vaccine, your clinic, patients, and/or 
patients’ insurance provers will be responsible for the coverage of vaccine costs. 
 
Confidentiality and Privacy  
We understand that information about you and your clinic is personal, and we are 
committed to protecting the privacy of that information. Any identifiable information that 
 54 
is obtained in connection with this study will remain confidential and will be disclosed 
only with your permission or as required by U.S. or State law. Examples of information 
that we are legally required to disclose include abuse of a child or elderly person. 
Information will be kept confidential by coding data with numbers, storing research 
materials in locked cabinets, and password-protecting data stored on a computer. When 
the results of the research are published or discussed in conferences, no information will 
be included that would reveal you or your clinic’s identity unless your specific 
permission for this activity is obtained.  
 
The information about your clinic that will be collected in this study includes: Total 
number of deliveries in 2021, vaccine availability for in-clinic administration, percentage 
of clinic patients with Medicaid insurance in 2021, percentage of clinic patients with self-
pay or no insurance in 2021, and EMR use.  
 
The information about your patients that will be collected in this study includes: Age, 
ethnicity/race, gestational age, parity, education level, employment status, health 
insurance status, history of previous influenza vaccines, receipt of the influenza vaccine 
prior to date of delivery, number of prenatal visits during the intervention period, 
gestational age on date of vaccination, and medical comorbidities. Patient subjects will be 
required to provide informed, written consent before we obtain this information. 
 
By signing this form, you authorize the use and/or disclosure of the information described 
above for this research study. The purpose for the uses and disclosures you are 
authorizing is to ensure that the information relating to this research is available to all 
parties who may need it for research purposes. All health care providers subject to 
HIPAA (Health Insurance Portability and Accountability Act) are required to protect the 
privacy of your information. The research staff at the Yale School of Medicine are 
required to comply with HIPAA and to ensure the confidentiality of your information.  
 
Voluntary Participation and Withdrawal 
You do not give up any of your legal rights by signing this form. Participating in this 
study is voluntary. You are free to choose not to take part in this study. Refusing to 
participate will involve no penalty or loss of benefits to which you are otherwise entitled 
(such as your health care outside the study, the payment for your health care, and your 
health care benefits). However, you will not be able to enroll in this research study as a 
study participant if you do not allow use of your clinic’s information as part of this study.  
 
If you do participate, you are free to stop and withdraw from this study at any time during 
its course. To withdraw from the study, you can call a member of the research team at 
any time and tell them that you no longer want to take part. The researchers may also 
withdraw you from participating in the research if necessary. Withdrawing from the study 
will involve no penalty or loss of benefits to which you are otherwise entitled. It will not 
harm your relationship with Yale New Haven Hospital. When you withdraw from the 
study, no new information will be gathered after that date. Information that has already 
been gathered may still be used and given to others until the end of the research study, as 




We have used some technical terms in this form. Please feel free to ask about anything 
you don’t understand and to consider this research and the consent form carefully – as 
long as you feel is necessary – before you make a decision.  
 
Authorization 
I have read (or someone has read to me) this form and have decided to participate in the 
project described above. Its general purposes, the particulars of my involvement, and 
possible hazards and inconveniences have been explained to my satisfaction. My 
signature also indicates that I have received a copy of this consent form.  
 




_____________________________________________  __________________________ 
Signature of Principal Investigator                                     Date 
 
                 or 
 
_____________________________________________  __________________________ 
Signature of Person Obtaining Consent                              Date 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator.  
 
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with 
someone other than the researchers to discuss problems, concerns, and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 














Appendix B: Clinic Questionnaire (Healthcare Providers) 
Clinic Name and Mailing Address:  
Your Name:  
Your Email Address:             Your Phone #: 
Credentials (circle one):    Physician         Nurse Midwife         Physician Associate                    
                                 Nurse Practitioner        Registered Nurse        Other: _____________ 
1. How many total deliveries (vaginal and operational) did your clinic complete in 
2021?  
________ total deliveries 
 
2. What was your clinic’s total number of patients in 2021? 
 
________ total patients 
  
3. What was your clinic’s total number of patients with Medicaid insurance in 
2021? 
 
________ total patients with Medicaid in 2021 
 
4. What was your clinic’s total number of patients with self-pay or no insurance in 
2021? 
 
________ total patients with self-pay or no insurance in 2021 
 
5. What is your clinic’s influenza vaccine availability for in-clinic administration? 
a. Vaccine always available for in-clinic administration 
b. Vaccine sometimes available for in-clinic administration 
c. Vaccine never available for in-clinic administration/referral to outside 
hospital or pharmacy only 
 
6. Does your clinic use an electronic medical record (EMR) for patient health 






Appendix C: Study Eligibility Screening Questionnaire (Patient Subjects) 
For use by a research team member when screening patients for study eligibility. If a 
patient responds with underlined question choices, then she most likely meets the 
inclusion criteria. 
 
1. Are you  18 years old? 
• Yes   • No 
 
2. Are you currently pregnant? 
• Yes   • No 
 
3. Are you able to read or understand English? 
• Yes   • No 
 
4. Have you received this season’s (2022-2023) influenza vaccine? 
• Yes   • No 
 
5. Do you have a known contraindication to the influenza vaccine? 
• Yes   • No 
 
6. Have you ever had an anaphylactic reaction to a vaccine? 
• Yes   • No 
 
7. Do you have a life-threatening allergy to a vaccine component or egg protein? 
• Yes   • No 
 
8. I am interested in participating in a research study and/or I am willing to be 
contacted by a research team member for more information. 
• Yes   • No 
 
9. If yes above (question 8), what is your first name, telephone number, and email 
address? 
 
First Name: ________________________________________________________ 
 
Telephone Number: _________________________________________________ 
 






Appendix D: Consent Form (Patient Subjects) 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR.1 (2016-2) 
 
YALE UNIVERSITY SCHOOL OF MEDICINE 
Study Title: Guidelines For Influenza Vaccination Uptake In Pregnant Women: A 
Cluster-Randomized Controlled Trial 
Principle Investigators: Katherine Campbell, MD, MPH 
Invitation to Participate and Description of Project 
You are invited to participate in a research study designed to examine the effect of a 
structured vaccine recommendation program for obstetric providers on the mean 
proportion of pregnant women who receive the influenza vaccination. You have been 
asked to participate because you are receiving prenatal care at one of our participating 
obstetric clinics. You have identified that you are  18 years old, currently pregnant, able 
to read or understand English, have no known contraindication to the influenza vaccine, 
and have not already received the 2022-2023 influenza vaccine. 
 
In order to decide whether or not you wish to be a part of this research study you should 
know enough about its risks and benefits to make an informed decision. This consent 
form gives you detailed information about the research study, which a member of the 
research team will discuss with you. This discussion should go over all aspects of this 
research: its purpose, the procedures that will be performed, any risks of the procedures, 
and possible benefits. Once you understand the study, you will be asked if you wish to 
participate; if so, you will be asked to sign this form. 
 
Description of Procedures 
If you agree to participate in this study, our research coordinator will provide you with a 
brief questionnaire with basic demographic information. Questions will include your age, 
parity, gestational age, ethnicity/race, influenza vaccination history, education level, 
insurance status, and employment status. 
 
You will then proceed to your prenatal care visit as usual. You may engage in a dialogue 
with your healthcare provider regarding the influenza vaccination during your pregnancy. 
You may be offered the vaccine for in-clinic administration, or you may be referred to a 
local hospital or pharmacy where you can obtain the vaccine at your earliest convenience. 
You may also be provided with fact sheets about the vaccine and its safety in pregnancy. 
More information about the Centers for Disease Control (CDC) and Prevention and the 
American College of Obstetricians and Gynecologists (ACOG)’s influenza vaccine 





After your delivery, blinded research staff will request limited, specific information about 
your medical care from your clinic’s electronic medical record (EMR). This information 
will be limited to your influenza vaccination status, your gestational age on the date of 
vaccination, the number of prenatal visits you had during influenza season, and your 
medical comorbidities. If your clinic does not use an EMR, a clinic staff member will 
collect this information from your medical chart and supply it to us.  
 
Risks and Inconveniences 
We do not anticipate significant risks associated with this study. Although pregnant 
women are a vulnerable research population, safety of the influenza vaccine in pregnancy 
has been shown repeatedly in medical literature, and our intervention simply promotes 
current World Health Organization (WHO), Centers for Disease Control (CDC), and 
American College of Obstetricians and Gynecologists (ACOG) guidelines. There are, 
however, minor risks associated with the influenza vaccine that participants should be 
aware of. Common side effects experienced by pregnant women are the same as those 
experienced by other people. These risks include:  




• Muscle aches 
• Nausea 
• Fatigue 
If side effects occur, they usually begin soon after the vaccine is given and last for 1-2 
days. Rarely, flu shots can cause serious problems like allergic reactions. Anyone with a 
severe, life-threatening allergy to the vaccine ingredients should not get the shot. 
Participation in this study may also involve risks that are not currently known.  
 
Benefits 
Potential benefits of this study include protection against the influenza virus, lower risk 
of influenza-associated adverse pregnancy outcomes, and lower risk of influenza-
associated morbidity and mortality, or illness and death, for you and your infant. 
 
Economic Considerations 
There are no costs associated with participation in this study. However, you and/or your 
insurance provider will be responsible for covering the cost of the influenza vaccine. 
These costs may vary based on vaccination site and insurance provider. For more 
information about the cost of your influenza vaccine, please speak with your healthcare 
and insurance providers. 
 
Confidentiality and Privacy  
We understand that information about your health is personal, and we are committed to 
protecting the privacy of that information. Any identifiable information that is obtained in 
connection with this study will remain confidential and will be disclosed only with your 
permission or as required by U.S. or State law. Information will be kept confidential by 
coding data with numbers, storing research materials in locked cabinets, and password-
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protecting data stored on a computer. When the results of the research are published or 
discussed in conferences, no information will be included that would reveal your identity 
unless your specific permission for this activity is obtained.  
 
The information about your health that will be collected in this study includes: Your age, 
ethnicity/race, influenza vaccination history, parity, gestational age, education level, 
current employment status, health insurance status, influenza vaccination receipt prior to 
date of delivery, gestational age on the date of vaccination, number of prenatal care visits 
during the influenza season, and medical comorbidities. 
 
By signing this form, you authorize the use and/or disclosure of the information described 
above for this research study. The purpose for the uses and disclosures you are 
authorizing is to ensure that the information relating to this research is available to all 
parties who may need it for research purposes. All health care providers subject to 
HIPAA (Health Insurance Portability and Accountability Act) are required to protect the 
privacy of your information. The research staff at the Yale School of Medicine are 
required to comply with HIPAA and to ensure the confidentiality of your information.  
 
Voluntary Participation and Withdrawal 
You do not give up any of your legal rights by signing this form. Participating in this 
study is voluntary. You are free to choose not to take part in this study. Refusing to 
participate will involve no penalty or loss of benefits to which you are otherwise entitled 
(such as your health care outside the study, the payment for your health care, and your 
health care benefits). However, you will not be able to enroll in this research study as a 
study participant if you do not allow use of your information as part of this study.  
 
If you do become a subject, you are free to stop and withdraw from this study at any time 
during its course. To withdraw from the study, you can call a member of the research 
team at any time and tell them that you no longer want to take part. The researchers may 
also withdraw you from participating in the research if necessary. Withdrawing from the 
study will involve no penalty or loss of benefits to which you are otherwise entitled. It 
will not harm your relationship with your doctors or Yale New Haven Hospital. When 
you withdraw from the study, no new health information identifying you will be gathered 
after that date. Information that has already been gathered may still be used and given to 
others until the end of the research study, as necessary to ensure the integrity of the study 
and/or study oversight.  
 
Questions 
We have used some technical terms in this form. Please feel free to ask about anything 
you don’t understand and to consider this research and the consent form carefully – as 
long as you feel is necessary – before you make a decision.  
 
Authorization 
I have read (or someone has read to me) this form and have decided to participate in the 
project described above. Its general purposes, the particulars of my involvement, and 
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possible hazards and inconveniences have been explained to my satisfaction. My 
signature also indicates that I have received a copy of this consent form.  
 




_____________________________________________  __________________________ 
Signature of Principal Investigator                                     Date 
 
                 or 
 
_____________________________________________  __________________________ 
Signature of Person Obtaining Consent                              Date 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator.  
 
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with 
someone other than the researchers to discuss problems, concerns, and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 

























Appendix E: Demographic Questionnaire (Patient Subjects) 
Participant Study ID (filled in by research staff): ________________________ 
 
1. What is your age? _________ 
 
2. What is your ethnicity/race? (check all that apply) 
• White/Caucasian   • Black/African American   • Hispanic/Latino  
• Other: __________________ 
 
3. What is the gestational age of your current pregnancy? ________ weeks 
 
4. How many pregnancies have you carried for >20 weeks, including deliveries? 
_______________ 
 
5. What is your education level? 
• Some high school   • High school graduate or equivalent   • Some college 
• Associate degree   • Bachelor’s degree    • Graduate or professional degree 
• Prefer not to answer 
 
6. What is your current employment status? 
• Employed   • Unemployed 
       
7. Do you currently have health insurance? 
• Yes   • No 
 
8. Have you ever received the influenza vaccine before? 
• Yes   • No  
 
9. If yes, when did you last receive the influenza vaccine? 
• Last influenza season   • <5 years ago   • 5 years ago  
















Appendix F: Talking with Pregnant Women About Vaccines Resource Guide 
 
 
Tal king with Pr egnant Women about Vaccines 
 
 
Influenza carries a large global disease burden and poses unique risks 
for pregnant women and infants.1,2 During pregnancy, physiologic 
changes like decreased functional residual lung capacity, mucus 
hypersecretion, increased cardiac output, and increased plasma blood 
volume alter the mother’s respiratory and cardiovascular systems. 
These physiologic changes, along with changes to the mother’s 
immune system, contribute to a modified response to infection and 
increased risk of complications during pregnancy.3  
 
The World Health Organization (WHO) and The Centers for Disease 
Control and Prevention (CDC) recommend that all pregnant women 
receive the influenza vaccine during pregnancy; however, 64.4% of 
pregnant women in the United States do not receive the vaccine, 
putting them and their infants at risk for developing severe illness and 
adverse pregnancy outcomes.4-6 Many women are not recommended, 
offered, or referred for the vaccine by their obstetric providers, which 
contributes to low vaccine uptake.6  
 
Researchers have investigated various interventions and their 
effectiveness at improving influenza vaccination uptake; however, 
current literature lacks sufficient randomized controlled trials. In 
neonatal and pediatric settings, the CDC offers providers structured 
recommendations, including communication tools to use with new 
parents.7 These recommendations have been successful in 
improving pediatric vaccine uptake in the United States, with rates 
of children 19-35 months receiving moth vaccinations greater than 
80-90%.7,8 Similar interventions have yet to be investigated 
thoroughly in the obstetric setting. 
 
Healthcare providers play a critial role in maintaining a clinic-wide 
commitment to communicating effectively about vaccines. Patients 
consider their healthcare providers to be their most trusted source of 
information when it comes to vaccines. You play a critical role in 
helping women choose vaccination.9 
 
You may feel that committing to challenging vaccine conversations are 
time-consuming and stressful amidst a day of providing important 
prenatal care. Because of this, we designed this easy-to-use resource 
guide with conversational techniques and resources for discussing 
vaccines with pregnant women .  
 
1. Assume women wil l  Vaccinate 
State which vaccines the patient shoul d receive. 
When discussing vaccines with pregnant women, it is best to 
remember that many women are planning to accept vaccines and to 
introduce the topic with that in mind. State the patient will receive the 
vaccine, as though you presume that she is ready to accept the 













2. Give your  str ong recommendation 
If  women expr ess concer ns, shar e your  str ong recommendation.  
State your strong recommendation. If appropriate and useful, you can 
add a statement that uses a mix of science and anecdote. Share the 
importance of the influenza vaccine to protect both the mother and her 
baby from life-threatening illness and adverse pregnancy outcomes. 










Instead of saying “What do you want to do about vaccines?” 
say, “You need the influenza vaccine today.” 
 
Instead of saying “Have you thought about the vaccines you 
need during pregnancy?” say,  
“You need the influenza vaccine during pregnancy.” 
 
 
“I strongly recommend you get this vaccine today…” 
“…This vaccine is very important to protect you and your baby 
from serious illness.” 
“…I believe in vaccines so strongly that I was vaccinated 
against influenza during my own pregnancy.” 
“…This office has given thousands of doses of vaccines and 
we have never seen a serious reaction.” 
  
 
Instead of saying “Have you thought about the 
vaccines you need during pregnancy?,” say “You 









3. Listen and respond to patients’  
questions 
Seek to under stand patients’  concer ns & pr ovide infor mation. 
Although research supports the safety of the influenza vaccine during 
pregnancy, you will encounter patients with questions.4,5,10,11  If a 
patient voices concerns or questions your strong recommendation, this 
doesn’t mean they won’t accept the vaccine. Sometimes patients 
simply want your answers to their questions. Your willingness to 
listen to their concerns will play an important role in building trust 
in you and your recommendation. 
 
When listening to patients, seek to understand the concerns behind 
their questions before responding. If you encounter questions you 
don’t know the answers to, or information from sources you are 
unfamiliar with, acknowledge the patient’s concerns and share what 
you do know. Offer to review the information they have found and, if 
possible, consider scheduling another appointment to discuss it further.   
 
What if  women refuse the vaccine? 
If pregnant women decline the influenza vaccine after your strong 
recommendation and dialogue, you can use the following strategies:  
 
• Continue the conversation about the vaccine at her next 
visit and restate your strong r ecommendation.  
 
• Inform women about clinical presentations of influenza, 
including early symptoms of cough, fever, sore  throat, 
runny or stuffy nose, headache, body aches, and fatigue.  
 
• Share CDC fact sheets Pregnant? You need a Flu Shot! 
and Pregnancy and Vaccination with patients. These 






Wrapping up the conversation 
Remember that success comes in many forms. It may mean that all 
pregnant women accept the influenza vaccine when you recommend 
it, or that they schedule the vacc ine for another day.  For very vaccine-
hesitant patients, success may simply mean agreeing to future 
conversations.  
 
Work with your patients to agree on at least one action, such as:  
 
• Scheduling another appointment, or  
 
• Encouraging the patient to read additional information you 
provide them. 
 
If a patient denies the vaccine once, this does not mean they always 
will. Continue to remind patients about the importance the influenza  
vaccination during pregnancy.  
 
 
This r esour ce guide was Cr eated with hel p f r om the CDC’ s infor mation 
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Appendix I: Email Reminder to Healthcare Providers 
Dear (Name of Healthcare Provider), 
 
We hope that you are having a wonderful week and we know that you are hard at work 
encouraging your prenatal patients to receive the influenza vaccine. The World Health 
Organization (WHO) and the Centers for Disease Control and Prevention (CDC) 
recommend that all pregnant women receive the influenza vaccine during pregnancy; 
however, 64.4% of pregnant women in the United States do not receive the vaccine, 
putting them and their infants at risk for developing severe illness and adverse 
pregnancy outcomes.1-3  
 
Many women are not recommended, offered, or referred for the vaccine by their 
obstetric providers, which contributes to low vaccine uptake.3  
 





Our team is here to help make flu vaccine conversations easy. Please tell us how we can 
help. 
 
•  I need more paper resource guides                  • I need a PDF copy of the resource 
guide 
• I need more paper CDC fact sheets                  • I need PDF copies of CDC fact sheets  
• I have specific questions for a member of the research team 
• Other: _____________________________________ 
 
Best, The Research Team 
 
1. Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza 
with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 
Influenza Season. MMWR Recomm Rep. 2019;68(3):1-21. 
 70 
2. World Health Organization. Vaccines Against Influenza WHO Position Paper - November 2012. Weekly Epidemiological 
Record. 2012;87(47):461-467. 
3. Centers for Disease Control and Prevention. Pregnant Women and Flu Vaccination, Internet Panel Survey, United States, 
November 2017. https://www.cdc.gov/flu/fluvaxview/pregnant-women-nov2017.htm#footnotes. Published 2017. Updated 
2017, November 28. Accessed. 
Appendix J: Data Collection Form  
 
Participant Study ID:  





(White/Caucasian, Black/African American, Hispanic/Latino, Other) 
 
Gestational Age  






(Some high school, High school graduate or equivalent, Some college, Associate degree, 





Health Insurance Status  
(Insured, Uninsured) 
 
History of Previous Influenza Vaccine  
(Yes, No) 
 
Date of Previous Influenza Vaccine  





(EMR, Clinic Medical Records) 
 
Influenza Vaccine Receipt before Date of Delivery 
(Yes, No) 
 
Gestational Age on Date of Vaccination 
(Number in Weeks) 
 























Appendix K: Sample Size Calculation 
Effect Size  Sample Size 
   
Number of Clinics 
Pregnant Women  
Per Clinic 
d 0.35  Intervention 5 50 
ICC 0.010  Control 5 50 
 
There is an 80.1% likelihood that the study will yield a statistically significant result. This 
projection is based on the following assumptions: 
The standardized effect size (d) is 0.35.  
The intracluster correlation coefficient (ICC) = 0.010.  
Each group (intervention and control) will include 5 clinics with 50 pregnant women per 
clinic.  
Criterion for statistical significance is alpha (2-tailed) set at 0.05.  
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